Institutional shares held 136 Million
1.97M calls
1.69M puts
Total value of holdings $16.2B
$235M calls
$201M puts
Market Cap $257B
2,151,000,064 Shares Out.
Institutional ownership 6.31%
# of Institutions 1,549


Latest Institutional Activity in NVS

Top Purchases

Q2 2025
Morgan Stanley Shares Held: 7.56M ($902M)
Q2 2025
Optiver Holding B.V. Shares Held: 515K ($61.5M)
Q2 2025
Bank Of Montreal Shares Held: 565K ($67.4M)
Q2 2025
Dimensional Fund Advisors LP Shares Held: 9.06M ($1.08B)
Q2 2025
Millennium Management LLC Shares Held: 841K ($100M)

Top Sells

Q2 2025
Cibc World Market Inc. Shares Held: 159K ($19M)
Q2 2025
New Vernon Capital Holdings Ii LLC Shares Held: 16.9K ($2.02M)
Q2 2025
Dodge & Cox Shares Held: 10.6M ($1.27B)
Q2 2025
Goldman Sachs Group Inc Shares Held: 2.54M ($303M)
Q2 2025
Franklin Resources Inc Shares Held: 4.24M ($506M)

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.


Insider Transactions at NVS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on NVS

Follow NOVARTIS AG and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NVS shares.

Notify only if

Insider Trading

Get notified when an Novartis Ag insider buys or sells NVS shares.

Notify only if

News

Receive news related to NOVARTIS AG

Track Activities on NVS